RMTI - Rockwell Medical, Inc.
| Previous Close | 3.600 |
| Open | 3.520 |
| Bid | 3.510 x 1000 |
| Ask | 3.530 x 900 |
| Day's Range | 3.400 - 3.527 |
| 52 Week Range | 3.400 - 6.920 |
| Volume | 106,323 |
| Avg. Volume | 156,721 |
| Market Cap | 197.998M |
| Beta (3Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.622 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of RMTI earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Rockwell Medical Inc Earnings Call
- Zacks•11 days ago
Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 33.33% and 11.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Rockwell Medical: 3Q Earnings Snapshot
The Wixom, Michigan-based company said it had a loss of 10 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $16.7 million in the period. The company's ...
- PR Newswire•11 days ago
Rockwell Medical, Inc. Reports Third Quarter 2018 Financial Results
WIXOM, Mich. , Nov. 9, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company") today reported financial results for the third quarter ended September 30, 2018 , and highlighted ...
- Zacks•18 days ago
Analysts Estimate Rockwell Medical (RMTI) to Report a Decline in Earnings: What to Look Out for
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•19 days ago
Rockwell Medical Appoints New Chief Financial Officer
WIXOM, Mich. , Nov. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Angus Smith has been appointed as Chief Financial ...
- PR Newswire•22 days ago
Rockwell Medical Schedules Third Quarter 2018 Conference Call
WIXOM, Mich. , Oct. 29, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) today announced that it will hold a conference call to discuss third quarter 2018 financial results on Friday, November ...
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on Rockwell Medical, Diamondback Energy, Steven Madden, Synaptics, Photronics, and Caleres — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•last month
Rockwell Medical Announces Financing Transaction
WIXOM, Mich., Oct. 15, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today announced that it has agreed to sell up to 7,556,675 units to The RBI Opportunities Fund, LLC, an affiliate of Richmond Brothers, Inc. ("Richmond") in a private placement, with each unit consisting of one share of common stock and a warrant to purchase 50% of a share of common stock. The units are being sold at $3.97 per unit, which is equivalent to the closing stock price of the Company's common stock on October 12, 2018, the last trading day prior to pricing this transaction. The warrants, which are not exercisable for six months from closing, have a strike price of $4.96 per full share of common stock and have a five-year term from issuance.
- PR Newswire•last month
Rockwell Medical Provides Update on IV Triferic
WIXOM, Mich., Oct. 12, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today provided an update on the status of the Company's development of an intravenous ("IV") formulation of the Company's proprietary drug Triferic®, which is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The Company is in the process of preparing a New Drug Application ("NDA") for IV Triferic and anticipates that it will file the NDA in the fourth quarter of 2018, which would result in a Prescription Drug User Fee Act ("PDUFA") action date in late 2019. "Based on feedback from a pre-NDA meeting with the FDA, we believe that we have an NDA package, including bioequivalence data, that would enable the FDA to review and act on this application before the end of 2019," said Stuart Paul, Rockwell Medical President and Chief Executive Officer.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RMTI earnings conference call or presentation 14-Aug-18 9:00pm GMT
Q2 2018 Rockwell Medical Inc Earnings Call
- PR Newswire•2 months ago
Rockwell Medical Appoints VP, Strategic Accounts
WIXOM, Mich., Oct. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Accounts, effective today, October 1, 2018. In this newly-established roll, Ms. Boardman will report to Stuart Paul, President & Chief Executive Officer of the Company. Ms. Boardman has substantial experience in renal, biotech and medical sales, sales management and large corporate account management throughout her 30-year career.
- Business Wire•2 months ago
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rockwell Medical, Inc. (“Rockwell Medical” or “the Company”) (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Rockwell Medical had knowledge that the Centers for Medicare and Medicaid Services would not pursue the Company’s plan for reimbursement for Triferic.
- Business Wire•2 months ago
Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Rockwell Medical, Inc. (RMTI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 25, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ: RMTI) securities between November 8, 2017, and June 26, 2018, inclusive (the “Class Period”). On June 27, 2018, Rockwell disclosed that its auditor resigned, and that the auditor claimed, among other things, that the estimated reserves in Rockwell’s Form 10-Q for the period ended March 31, 2018 were incorrect. The Complaint filed in this class action alleges that the Company made false and misleading statements to the market.
- ACCESSWIRE•2 months ago
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Rockwell Medical, Inc. ("Rockwell Medical" or "the Company") (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 16, 2018, and June 26, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.
- ACCESSWIRE•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Rockwell Medical, Inc. of Class Action Lawsuit and Upcoming Deadline - RMTI
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Pomerantz LLP announces that a class actionlawsuit has been filed against Rockwell Medical, Inc. ("Rockwell" or the "Company") (RMTI) and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and index under 18-cv-04993, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Company securities between November 8, 2017 and June 26, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- GlobeNewswire•2 months ago
CLASS ACTION UPDATE for RMTI, TTPH, HMNY and GDS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Sept. 23, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...
- ACCESSWIRE•2 months ago
4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 21, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Rockwell Medical, Inc. ("Rockwell Medical" or "the Company") (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 16, 2018, and June 26, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.
- GlobeNewswire•2 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, TTPH, HMNY, PM and QRTEA
NEW YORK, Sept. 21, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Rockwell Medical, Inc. (RMTI) and Lead Plaintiff Deadline – September 25, 2018
NEW YORK, Sept. 21, 2018-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Rockwell Medical, Inc. and certain of its officers, ...
- GlobeNewswire•2 months ago
RMTI DEADLINE: Rosen Law Firm Reminds Rockwell Medical, Inc. Investors of September 25 Deadline in Class Action - RMTI
NEW YORK, Sept. 20, 2018-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Rockwell Medical, Inc. between March 16, 2018 and June 26, 2018, inclusive of the important ...
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: ZN RMTI TTPH ABBV HMNY GDS PVG OPK USAT TRCO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Sept. 20, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...
- ACCESSWIRE•2 months ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 20, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Rockwell Medical, Inc. ("Rockwell Medical" or "the Company") (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 16, 2018, and June 26, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.
- ACCESSWIRE•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Rockwell Medical, Inc. of Class Action Lawsuit and Upcoming Deadline - RMTI
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Rockwell Medical, Inc. ("Rockwell" or the "Company") (RMTI) and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and index under 18-cv-04993, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Company securities between November 8, 2017 and June 26, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE•2 months ago
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 19, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Rockwell Medical, Inc. ("Rockwell Medical" or "the Company") (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 16, 2018, and June 26, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.
